New Delhi: The infamous miracle drug hydroxychloroquine (HCQ) which was touted by many to be a ‘game-changer’ against the fight against COVID-19 has no positive effect with regards to two new studies on Friday.
A study released on Friday by researchers in France stated that they monitored 181 patients suffering from pneumonia due to novel coronavirus who needed oxygen. Out of the 181 patients, 84 were treated with HCQ and 97 were not. After the treatment, however, the patients showcased no meaningful difference in groups who were transferred to intensive care or in those who developed acute respiratory distress syndrome within 10 days.
The second study which was made in China had split 150 patients infected with the coronavirus into two groups and found that there were some adverse reactions to normal treatment in the group administered with HCQ. However, there were no differences found in the severity and the duration of symptoms in each of the two groups.
Yet another research which took place in New York looked at 1,438 patients from 25 hospitals between March 15 and 28 showcased no visible difference in the patients. 735 patients received HCQ with another drug azithromycin, and 271 were given just HCQ and the rest 221 acted as a control group with just azithromycin. Unfortunately, the health professionals did not see any benefits of HCQ with or without azithromycin.
The drug HCQ falls in a class of medications that were first used to prevent and treat malaria. Nowadays, it is being used to treat rheumatoid arthritis and some symptoms of lupus and childhood arthritis.